Steven Cohen’s Alto Neuroscience ANRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.3M Sell
502,950
-137
-0% -$3.17K 0.01% 1114
2026
Q1
$11.3M Sell
503,087
-1,103,867
-69% -$20.5M 0.01% 1158
2025
Q4
$28.6M Buy
1,606,954
+274,517
+21% +$3.46M 0.03% 681
2025
Q3
$5.36M Buy
1,332,437
+2,682
+0.2% +$8.89K 0.01% 1043
2025
Q2
$2.93M Buy
1,329,755
+89,702
+7% +$213K 0.01% 1160
2025
Q1
$2.68M Sell
1,240,053
-452,100
-27% -$1.62M 0.01% 1150
2024
Q4
$7.16M Buy
1,692,153
+714,461
+73% +$4.46M 0.02% 827
2024
Q3
$11.2M Sell
977,692
-72,345
-7% -$885K 0.03% 608
2024
Q2
$11.2M Sell
1,050,037
-74,963
-7% -$976K 0.03% 566
2024
Q1
$17.3M Buy
+1,125,000
New +$17.6M 0.04% 497

Other funds holding ANRO

Steven Cohen's ANRO Position: Q2 2026 in Review

Steven Cohen reduced its Alto Neuroscience (ANRO) stake by 0.03% in Q2 2026, selling an estimated $3.17K and leaving 502,950 shares worth $13.3M. The position accounts for 0.01% of the portfolio, ranked #1114.

Steven Cohen first reported a position in ANRO in Q1 2024 and has held it in 10 quarters since. The position peaked at $28.6M in Q4 2025. 113 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Steven Cohen held 502,950 shares of Alto Neuroscience worth $13.3M as of Q2 2026.
  • Steven Cohen sold 137 Alto Neuroscience shares in Q2 2026, an estimated $3.17K.
  • Alto Neuroscience made up 0.01% of Steven Cohen's portfolio in Q2 2026, its #1114 holding.
  • Steven Cohen first reported a position in Alto Neuroscience in Q1 2024 and has held it in 10 quarters since.
  • Steven Cohen's Alto Neuroscience position peaked at $28.6M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.